Antibiotic susceptibility patterns of *Staphylococcus aureus* strains isolated at the Yaounde Central Hospital, Cameroon: a retro prospective study

Michel Kengne1,6, Olivier Fotsing1, Thérèse Ndomgue1,2, Julius Mbekem Nwobegahay1,3

1Department of Medical Microbiology and Immunology, School of Health Sciences, Catholic University of Central Africa, Yaounde, Cameroon, 2Technicians school, Yaoundé, Cameroon, 3Military Health Research Center (CRESAR), Yaounde, Cameroon

Corresponding author: Michel Kengne, Department of Medical Microbiology and Immunology, School of Health Sciences, Catholic University of Central Africa, Yaoundé, Cameroon

Key words: *Staphylococcus aureus*, antibiotics susceptibility, Methicillin-resistant *Staphylococcus aureus*, methicillin-sensitive *Staphylococcus aureus*, Yaounde

Received: 09/04/2018 - Accepted: 13/02/2019 - Published: 05/03/2019

Abstract

Introduction: *Staphylococcus aureus* is an important pathogen responsible for hospital and community acquired infection(s). Emerging resistance to methicillin in this organism has left physicians with few therapeutic alternatives to treat infections caused by it. This study was aimed at determining the antibiotic susceptibility patterns of *Staphylococcus aureus* strains isolated at the Yaounde Central Hospital, Cameroon. Methods: from January 2014 to November 2016, a total of 250 non repeated strains were isolated from various clinical specimens. Isolates and antibiotic susceptibility profiles were identified through standard microbiological techniques. Results: methicillin-resistant *Staphylococcus aureus* (MRSA) and methicillin-sensitive *Staphylococcus aureus* (MSSA) accounted respectively for 80% (201/205) and 20% (49/205) of the total strains isolated. MRSA strains displayed high resistance to cefoxitin (100%), cotrimoxazole (89%), vancomycin (79.7%), lincomycin (70.3%), tobramycin (72.5%), doxycycline (68.0%), kanamycin (69.7%) and erythromycin (55.7%). In contrast, a high susceptibility was observed with rifampicin (82.6%). KTG (42.3%) and constitutive MLSB (17.4%) were the most frequent phenotypes recorded. Conclusion: our results show that the carriage of acquired MRSA infections predominates in this population. Despite the noticeable multiresistance of MRSA strains to antibiotics, rifampicin remains the drugs of choice for the therapy of acquired MRSA infections in this setting. In order to slow down antimicrobial resistance, surveillance studies for antimicrobial susceptibility remains essential to identify resistance and inform policy on resistance.
Introduction

Staphylococcus aureus is one of the organisms most frequently encountered in hospital and community acquired infection, especially in elderly individuals [1]; rates of Staphylococcus aureus infection have increased during the past 2 decades [2]. Bacteremia due to S. aureus has been reported to be associated with mortality rates of 15%-60% [3]. Infections with antibiotic-resistant organisms are thought to result in higher morbidity and mortality rates than are similar infections with antibiotic-susceptible strains [4]. In the early 1940s the introduction of benzylpenicillin (penicillin G) temporarily solved the problem of staphylococcal infections, but the continued use of this agent caused the selection of resistant strains, which produced penicillinase (β-lactamase) [5]. Resistance to methicillin among S. aureus isolates is a growing problem and poses a significant threat for effective treatment of several difficult-to-treat infections in humans [6]. High mortality rates associated to MRSA have been reported. According to the National Strategy for Combating Antibiotic Resistant Bacteria [7], there were more than 80,000 invasive MRSA infections and 11,285 related deaths in 2011. An understanding of the magnitude of the problem requires national studies to estimate the incidence of the infection and to identify antibiotic resistance. In Cameroon, there is a paucity of data on this public health issue. The aim of this study was to determine the antibiotic susceptibility patterns of Staphylococcus aureus’s strains isolated at the Yaounde Central Hospital, Cameroon.

Methods

Samples collection: this cross-sectional retrospective study was carried out on strains of S. aureus isolated from pathological products of patients between January 2014 and November 2016 at the Yaounde Central Hospital (YCH). Data dealing with the retrospective survey were obtained from the hospital’s data base, over a period of 28 months (January 2014-May 2016). The prospective part of the survey was conducted during a period of 6 months (June to November 2016). Participants were those attending the hospital for a bacteriological examination. Sociodemographic data were collected using a designed questionnaire. Ethical clearance was obtained from the Institutional Ethics Committee for Human Health Research of the Catholic University of Central Africa. Authorization to collect samples was obtained from YCH. Informed consent was obtained from all the study participants. Specimens were collected from both in and out patients as described by Rémic [8]. These included blood samples, pus swabs, urine samples, ear discharge, throat swab, aspirates, urethral swabs, vaginal swabs and semen.

Isolation and identification of Staphylococcus aureus: the clinical specimens were inoculated onto plates of mannitol salt agar (MSA); they were incubated at 37°C for 24h. All colonies from primary culture were purified by subculturing onto MSA medium and incubating at 37°C for 24h to 48h [9].

Morphological characteristics: the smear was prepared from the isolated culture on clean grease free microscopic glass slide and stained with Gram’s method of staining. The stained smear was observed under the microscope. Smear revealed Gram positive, spherical cells arranged in irregular clusters resembling to bunch of grapes.

Biochemical examination: biochemical tests were performed to confirm S. aureus using Catalase test, Coagulase test and DNase test.

Antibiogram pattern of S. aureus to some antimicrobial agents: the susceptibility of isolates to different anti-microbial agents was done by disk diffusion method using commercial disks [10] and interpreted according to EUCAST [11]. The results were recorded as susceptible(S), susceptible dose dependent (SDD) and resistant (R). Pure colonies of S. aureus cultures were inoculated in peptone water and incubated at 37°C to get turbidity equal to 0.5 on the McFarland scale (108 CFU/ml). A sterile cotton swab was dipped into the inoculation, and the excess was removed by pressing the swab to the sides of the tube. The entire Mueller Hinton agar surface was swabbed. The inoculation was allowed to dry for 15 min. Antibiotic discs were applied on the medium. The plates were incubated at 37°C and examined after 18-24 h. The antimicrobial agents tested were the following: cefoxitin (30µg), gentamicin (15µg), kanamycin (30 µg), tobramycin (10 µg), erythromycin (15 µg), lincomycin (15 µg), pristinamycin (15 µg), ciprofloxacin (5µg), vancomycin (30 µg), trimethoprim-sulfamethoxazole (25 µg), chloramphenicol (30 µg), rifampicin (5µg) and fusidic acid (30 µg). The susceptibility to methicillin was tested using a 30 µg cefoxitin disk. An inhibition halo < 25 mm was considered methicillin resistant. Macrolide, Lincosamide, Streptogramine B (MLSB) and aminoglycosides resistance phenotypes were identified as described by Courvalin et al[12]. The quality control of discs used was performed using Staphylococcus aureus (ATCC 25923).
Results

In total, 250 non repeated strains of *S. aureus* were included in the study. 19.6% (49/250) strains were considered as methicillin susceptible (MSSA). MRSA accounted for 80.4% (201/250) of the total strains among which 56.2% (113/201) were isolated from male and 43.8% (88/201) from female. There was no predominance of carriage of acquired MRSA infections in male compared to female (p > 0.05) as shown in Table 1. The frequency of MRSA according to clinical specimen is detailed in Table 2. High percentage of isolation of MRSA were obtained from pus swabs 28, 8% (58/201), vaginal swabs 25.4% (51/201) and urethral swabs 25.4% (51/59), while ear discharge gave lower percentage 0.5% (1/201). No statistical significance was found between the frequency of MRSA isolates and the clinical specimen (p > 0.05). Distribution results of the frequency of MRSA isolates according to the hospital ward (Table 3) showed that the high percentage of isolates was from out patients 49.3% (99/201). There was no significant difference (P > 0.05) between numbers of isolation in different hospital ward. In this study, MRSA isolates were found variably resistant to the antibiotics tested. High sensitivity was observed towards rifampicin (82.59%). In contrast, a high resistance of the isolates was seen with cefoxitin (100%), cotrimoxazole (89%), vancomycin (79.7%), lincomycin (70.3%), tobramycin (72.5%), doxycycline (68.0%), kanamycin (69.7%) and erythromycin (55.7%) (Table 4). Of the 201 MRSA isolates, two main resistance phenotypes were identified among the macrolides and aminoglycosides. 17.4% (35/201) exhibited the constitutive resistant (cMLSB) phenotypes and 42.3% (85/201) the Kanamycin-Tobramycin-Gentamicin (KTG) resistant phenotypes (Table 5).

Discussion

*S. aureus*, one of the most common nosocomial and community-acquired pathogens has now emerged as an ever-increasing problem due to its increasing resistance to several antibiotics. This study determined the susceptibility pattern of *S. aureus* strains isolated from different clinical specimen in a tertiary hospital to provide physicians with up to date information about the local data of antimicrobial resistance of this pathogen. Of the 250 strains of *S. aureus* studied, 19.6% (49/250) strains were methicillin susceptible and 80.4% (201/250) were methicillin resistant. This study showed a high rate of MRSA which seems to be similar to findings of 72% by Njoungang [1], 76% by Gonsu [13], 65.7% by Asiimwe [14], 30.7% by Akindolire [15] and 32.5% by Eshetie [16]. As compared to present findings, lower rate of MRSA have been reported by Elbach [17], Leibler [18] and Ravensbergen [19] who found 2%, 8.3% and 10% rate respectively. It has been noticed that the proportion of MRSA has increased worldwide since the past two decades and the rate varies markedly across different countries and among hospitals of the same country [20, 21]. Improper infection prevention practices in the hospital set up, indiscriminate use of antibiotics; intravascular catheterizations, hospitalization in intensive care unit contribute in the emergence of MRSA [22]. These factors as well as the difference in the study population may explain these variations. Treatment decisions in MRSA infections require consideration of the prevalence and resistance profile of local strains. In this study, a high level of drugs resistance was found especially with vancomycin (79.70%) which is the first-line antibiotic for MRSA bacteremia treatment. This result contrasts with those reported by Karimi *et al* [23] and Swanston [24] where MRSA isolates were found susceptible to vancomycin. The high resistance of isolates to antibiotics could be due to the wide use of these drugs for the treatment of staphylococcal infections in our set up, as wide consumption of antibiotics results to the emergence of antibiotics resistant Staphylococcus species due to selective pressure.

In this study the rate of iMLSB among MRSA was found to be 4.5%. Varying prevalence rates of iMLSB have been reported in different other studies; 2.1% from Brazil [25], 8% from Jamaica [26], 18.2% from Nepal [27], 25% from Cameroon [1], 28.6% from Iran [28], 20.7% [29] and 24.3% [30] from India. Higher iMLSB prevalence of 37.5% from India [31] and 91% from Japan [32] has also been reported. A comparatively low prevalence of inducible resistance in this study could be due to the geographical variations of circulatory clones. MRSA isolates showed high rates of resistance to aminoglycoside agents. The study of resistance phenotypes of our MRSA to these drugs showed three types. 9 strains (4.5%) had a phenotype K, due to the production of the enzyme-Aminoglycoside phosphotransferase APH (3')-III. 30(14.9%) were resistant to kanamycin and tobramycin, KT is the phenotype expressed by the
production of the enzyme-Aminoglycosides nucleotidyltransferases ANT (4') (4")", while 85 strains (42.3%) expressed the KTG phenotype and were resistant to the three antibiotics (kanamycin, tobramycin, gentamicin) due to the bifunctional enzyme APH (2") - Aminoglycosides acetyltransferases AAC (6') [33]. Our results are supported by those of Ida et al[34] and Shaw et al [35] who showed that most MRSA isolates seemed likely to produce AAC(6')/APH(2"), with or without ANT(4')-I, among the five kinds of aminoglycoside-modifying enzymes. In general, a beta-lactam or vancomycin often is combined with an aminoglycoside due to their synergistic effect and increased rates of killing in serious staphylococcal infections [36]. However, considering the high rates of resistance to the aminoglycosides, the addition of an aminoglycoside for the treatment of MRSA infections may be unpredictable in our set up.

**Conclusion**

The burden of methicillin resistant *Staphylococcus aureus* is considerably high in this setting. The isolated strains were found to be resistant to cefoxitin, cotrimoxazole, vancomycin, lincomycin, tobramycin, doxycyclin, kanamycin and erythromycin. Rifampicin is advised for the therapy of acquired MRSA infections in this setting. Appropriate use of antibiotics remains the key to reduce the spread of multidrug resistant strains, methicillin resistant *Staphylococcus aureus* in particular. Furthermore, an antimicrobial stewardship program will be beneficial for Cameroon to promote the appropriate use of antimicrobials.

**What is known about this topic**

- Bacteremia due to methicillin resistant *S. aureus* has been reported to be associated with high mortality rates;
- Resistance to methicillin among *S. aureus* isolates is a growing problem;
- Resistance to the newer antimicrobial-agents such as vancomycin are being reported.

**What this study adds**

- The burden of methicillin resistant *Staphylococcus aureus* is considerably high in this setting;
- Methicillin resistant *Staphylococcus aureus* are resistant to cefoxitin, cotrimoxazole, vancomycin, lincomycin, tobramycin, doxycyclin, kanamycin and erythromycin;
- Rifampicin is the drug of choice for the therapy of acquired MRSA infections in this setting.

**Competing interests**

The authors declare no competing interest.

**Authors’ contributions**

Michel Kengne conceived, designed, financed the study and produced the first draft of this manuscript. Olivier Fotsing and Thérèse Ndomgue performed the sample collection, the laboratory assays and the data analysis and interpretation. Julius Mbekem Nwobegahay corrected the research proposal before the study and did a thorough review of the manuscript. All the authors have read and agreed to the final manuscript.

**Acknowledgments**

Special thanks are due to the Director of the Yaounde Central Hospital who granted the research authorization for this study.

**Tables**

| Table | Description |
|-------|-------------|
| Table 1 | distribution of *S. aureus* by gender |
| Table 2 | distribution of *S. aureus* by specimen type |
| Table 3 | distribution of *S. aureus* per hospital ward |
| Table 4 | susceptibility pattern of MRSA isolates to antibiotics |
| Table 5 | MRSA isolates resistance phenotypes against macrolides and aminoglycosides |
References

1. Njoungang LL, NwobegahayMbekem J, Ayangma RC, NjukengAchianga P, Kengne M, Mbozo'o Abeng E, Mama EA, Tchouamo M, Ter Goon D. Prevalence and antibiotic resistance patterns of strains of Staphylococcus aureus isolated at the Yaounde Military Hospital, Cameroon. Microbiol Res Int. 2015; 3(4): 56-63. Google Scholar

2. NNIS System. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control. 1999; 27(6): 520-532. PubMed

3. Julander I. Unfavourable prognostic factors in Staphylococcus aureus septicemia and endocarditis. Scand J Infect Dis. 1985; 17(2): 179-187. PubMed | Google Scholar

4. Acar JF. Consequences of bacterial resistance to antibiotics in medical practice. Clin Infect Dis. 1997; 24(1): 17-18. PubMed | Google Scholar

5. Brumfitt W, Hamilton-Miller J. Methicillin-Resistant Staphylococcus aureus. N Engl J Med. 1989; 320(18): 1188-1196. PubMed | Google Scholar

6. Niu H, Yee R, Cui P, Tian L, Zhang S, Shi W, Sullivan D, Zhu B, Zhang W, Zhang Y. Identification of Agents Activeagainst Methicillin-Resistant Staphylococcus aureus USA300 from a Clinical Compound Library. Pathogens. 2017; 6(3): pii: E44. PubMed | Google Scholar

7. National strategy for combating antibiotic resistant bacteria, 2014.

8. Fnac. Rémic. Référentiel en microbiologie médicale. 4ème édition. 2010.

9. Abbas BA, Khudor MH and Hanoon BM. Isolation and identification of Staphylococcus aureus from bovine and the detection of its coagulase gene (coa) using polymerase chain reaction (PCR). Sci Res Essays. 2014; 9(20): 864-868. Google Scholar

10. Bauer AW, Kirby WMM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized Acknowledgements single disk method. Amer J Clin Pathol. 1966; 45(4): 493-496. PubMed | Google Scholar

11. EUCAST. Comité de l’antibiogramme de la Société Française de Microbiologie. Recommendations. 2014.

12. Courvalin P and Ledernr R. Antibiogramme. 3ème edition. 2012.

13. Gonsu KH, Ndongo GA, Adiogo D, Toukam M, Ndze VN, Kechia AF. Carriage of multi-drug resistant bacteria among medical staff of the Yaounde University Teaching Hospital, Cameroon. J Bacteriol Res. 2013; 5(5): 62-67. Google Scholar

14. Asiimwe BB, Baldan R, Trovato A, Cirillo DM. Molecular epidemiology of Panton-Valentine Leukocidin-positive community-acquired methicillin resistant Staphylococcus aureus isolates in pastoral communities of rural south western Uganda. BMC Infect Dis. 2017; 17(1): 17-24. PubMed

15. Akindolire AE, Tongo O, Dada-Adegbola H, Akinyinka O. Etiology of early onset septicemia among neonates at the University College Hospital, Ibadan, Nigeria. J Infect Dev Ctries. 2016; 10(12): 1338-1344. PubMed | Google Scholar

16. Eshetie S, Tarekegn F, Moges F, Amsalu A, Birhan W, Huruy K. Methicillin resistant Staphylococcus aureus in Ethiopia: a meta-analysis. BMC Infect Dis. 2016; 16(1): 689. PubMed | Google Scholar

17. Eibach D, Nagel M, Hogan B, Azuure C, Krumkamp R, Dekker D, Gajdiss M, Brunke M, Sarpong N, Owusu-Dabo E, May J. Nasal Carriage of Staphylococcus aureus among Children in the Ashanti Region of Ghana. PLoS One. 2017; 12(1): e0170320. PubMed | Google Scholar

18. Leibler JH, León C, Cardoso LJP, Morris JC, Miller NS, Nguyen DD, Gaeta JM. Prevalence and risk factors for MRSA nasal colonization among persons experiencing homelessness in Boston, MA. J Med Microbiol. 2017; 66(8): 1183-1188. PubMed | Google Scholar
19. Ravensbergen SJ, Berends M, Stienstra Y, Ott A. High prevalence of MRSA and ESBL among asylum seekers in the Netherlands. PLoS One. 2017; 12(4): e0176481. PubMed | Google Scholar

20. Rajaduraipandi et al. Prevalence and antimicrobial susceptibility pattern of methicillin resistant Staphylococcus aureus: a multicentre study. Indian J Med Microbiol. 2006; 24(1): 34-38. PubMed | Google Scholar

21. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009; 7(9): 629-641. PubMed | Google Scholar

22. Catry et al. Risk Factors for Methicillin Resistant Staphylococcus aureus: a multi-laboratory study. PLOS ONE. 2014; 9(2): e89579. PubMed | Google Scholar

23. Karimi M, Esfahani BN, Halaji M, Mobasherizadeh S, Shahin M, Havaei SR, Shokri D, Havaei SA. Molecular characteristics and antibiotic resistance pattern of Staphylococcus aureus nasal carriage in tertiary care hospitals of Isfahan, Iran. Infez Med. 2017; 25(3): 234-240. PubMed | Google Scholar

24. Swanston WH. Methicillin resistant Staphylococcus aureus. The West Indian Med J. 1999; 48(1): 20-22. PubMed

25. Bottega A, Rodrigues Mde A, Carvalho FA, Wagner TF, Leal IA, Santos SO, Rampelotto RF, Hörner R. Evaluation of constitutive and inducible resistance to clindamycin in clinical samples of Staphylococcus aureus from a tertiary hospital. Rev Soc Bras Med Trop. 2014; 47(5): 589-592. PubMed | Google Scholar

26. Brown PD. Multiple-locus VNTR Analyses of Methicillin-resistant Staphylococcus aureus from Jamaica. Infect Dis (Auckl). 2015; 8: 31-38. PubMed | Google Scholar

27. Mohapatra TM, Shrestha B, Pokhrel BM. Constitutive and inducible clindamycin resistance in Staphylococcus aureus and their association with methicillin-resistant S aureus (MRSA): experience from a tertiary care hospital in Nepal. Int J Antimicrob Agents. 2009; 33(2): 187-189. PubMed | Google Scholar

28. Navidinia M. Detection of inducible clindamycin resistance (MLSBI) among methicillin-resistant Staphylococcus aureus (MRSA) isolated from health care providers. J Paramedical Sci. 2015; 6(1): 91-96. Google Scholar

29. Koppada R, Meeniga S, Anke G. Inducible clindamycin resistance among Staphylococcus aureus isolated from various clinical samples with special reference to MRSA. Sch J App Med Sci. 2015; 3(6D): 2374-80.

30. Gade ND, Qazi MS. Inducible clindamycin resistance among Staphylococcus aureus isolates. Indian J Basic Appl Med Res. 2013; 8(2): 961-967. Google Scholar

31. Lall M, Sahni AK. Prevalence of inducible clindamycin resistance in Staphylococcus aureus isolated from clinical samples. Med J Armed Forces India. 2014; 70(1): 43-47. PubMed | Google Scholar

32. Shoji et al. High rate of inducible clindamycin resistance in Staphylococcus aureus isolates-a multicenter study in Tokyo. Japan J Infect Chemother. 2015; 21(2): 81-83. PubMed | Google Scholar

33. Aouati H, Arafa N, Benlabeled K, Boulahrouf A, Bousseboua H. Methicillin-resistant staphylococcus aureus at university Hospital Center Ben Badis of Constantine-Algeria. Rev Tun Infectiol. 2010; 4(4): 129-133.

34. Ida T, Okamoto R, Shimauchi C, Okubo T, Kuga A, Inoue M. Identification of aminoglycoside-modifying enzymes by susceptibility testing: epidemiology of methicillin-resistant Staphylococcus aureus in Japan. J ClinMicrobiol. 2001; 39(9): 3115-3121. PubMed | Google Scholar

35. Shaw KJ, Rather PN, Hare RS, Miller GH. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev. 1993; 57(1): 138-163. PubMed | Google Scholar

36. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998; 339(8): 520-532. PubMed | Google Scholar
### Table 1: distribution of *S. aureus* by gender

| Gender  | Number of *S. aureus* isolates | Number of MRSA isolates | Percentage (% MRSA) | Statistics |
|---------|---------------------------------|-------------------------|---------------------|------------|
| Male    | 139                             | 113                     | 56.2                | $X^2 = 0.54, df = 2, p = 0.7$ |
| Female  | 111                             | 88                      | 43.8                |            |
| Total   | 250                             | 201                     | 100                 |            |

### Table 2: distribution of *S. aureus* by specimen type

| Specimen         | Number of *S. aureus* isolates | Number of MRSA isolates | Percentage (% MRSA) | Statistics |
|------------------|---------------------------------|-------------------------|---------------------|------------|
| Throat swabs     | 5                               | 3                       | 1.49                |            |
| Aspirates        | 9                               | 7                       | 3.48                |            |
| Ear discharge    | 1                               | 1                       | 0.50                |            |
| Vaginal swabs    | 61                              | 51                      | 25.37               |            |
| Urethral swabs   | 59                              | 51                      | 25.37               |            |
| Pus swabs        | 74                              | 58                      | 28.86               |            |
| Blood            | 8                               | 5                       | 2.49                |            |
| Semen            | 16                              | 12                      | 5.97                |            |
| Urine            | 17                              | 13                      | 6.47                |            |
| TOTAL            | 250                             | 201                     | 100                 | $X^2 = 10.11, df = 16, p = 0.8.$ |

### Table 3: distribution of *S. aureus* per hospital ward

| Hospital ward                | Number of *S. aureus* isolates | Number of MRSA isolates | Percentage (% MRSA) | Statistics |
|-------------------------------|---------------------------------|-------------------------|---------------------|------------|
| General Medicine             | 82                              | 61                      | 30.3                |            |
| Gynaecology                  | 19                              | 15                      | 7.5                 |            |
| Out patients                 | 119                             | 99                      | 49.3                |            |
| Surgery                      | 20                              | 19                      | 9.5                 |            |
| Yaounde Emergency Center     | 10                              | 7                       | 3.5                 |            |
| Total                        | 250                             | 201                     | 100                 | $X^2 = 14.38, df = 8, p = 0.07$ |
### Table 4: Susceptibility Pattern of MRSA Isolates to Antibiotics

| Antibiotics  | Number of MRSA isolates | MRSA (S) | MRSA (R) | MRSA (SDD) |
|--------------|-------------------------|----------|----------|------------|
|              | n                       | %        | n        | %          | n          |
| Rifampicin   | 201                     | 166      | 82.59    | 31         | 15.42      | 4          | 1.99       |
| Ciprofloxacin| 199                     | 129      | 64.82    | 53         | 26.63      | 17         | 8.54       |
| Chloramphenicol| 192                  | 108      | 56.25    | 70         | 36.46      | 14         | 7.29       |
| Gentamicin   | 201                     | 108      | 53.73    | 89         | 44.28      | 4          | 1.99       |
| Pristinamycin| 195                     | 102      | 52.31    | 74         | 37.95      | 19         | 9.74       |
| Fusidic acid | 198                     | 94       | 47.47    | 86         | 43.43      | 18         | 9.09       |
| Erithromycin | 199                     | 75       | 37.69    | 111        | 55.78      | 13         | 6.53       |
| Kanamycin    | 195                     | 52       | 26.67    | 136        | 69.74      | 7          | 3.48       |
| Doxycyclin   | 197                     | 49       | 24.87    | 134        | 68.02      | 14         | 7.11       |
| Tobramycin   | 189                     | 43       | 22.75    | 137        | 72.49      | 9          | 4.76       |
| Lincomycin   | 185                     | 42       | 22.70    | 130        | 70.27      | 13         | 7.03       |
| Vancomycin   | 197                     | 26       | 47.73    | 157        | 79.70      | 14         | 7.11       |
| Cotrimoxazol | 200                     | 15       | 07.50    | 178        | 89.00      | 7          | 3.50       |
| Cefoxitin    | 201                     | 0        | 0        | 201        | 100        | 0          | 0          |

### Table 5: MRSA Isolates Resistant Phenotypes Against Aminoglycosides

| Macrolides | Erythromycin | Lincomycin | Pristinamycin | Kanamycin | Tobramycin | Gentamicin |
|------------|--------------|------------|---------------|-----------|------------|------------|
|            | Phenotype/ mechanism | Number of MRSA isolates | Percentage (%) | Total |
| R          | R            | S          | MLSB constitutive | 35     | 17.4       | 201        |
| R          | S            | S          | MLSB inductible | 9      | 4.5        | 201        |
| S          | S            | S          | Wild type      | 19     | 9.4        | 201        |
| Aminoglycosides | Kanamycin | Tobramycin | Gentamicin phenotype | Number of MRSA isolates | Percentage (%) | Total |
| R          | R            | R          | KTG           | 85     | 42.3       | 201        |
| R          | R            | S          | KT            | 30     | 14.9       | 201        |
| R          | S            | S          | K             | 9      | 4.5        | 201        |
| S          | S            | S          | Wild type     | 30     | 14.9       | 201        |